Deutsche Bank
NRIX icon

Deutsche Bank’s Nurix Therapeutics NRIX Stock Holding History

Deutsche Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.74M Buy
368,447
+216,994
+143% +$5.41M ﹤0.01% 1029
2026
Q2 		$3.67M Sell
151,453
-2,143,571
-93% -$36.5M ﹤0.01% 1539
2026
Q1 		$35.6M Sell
2,295,024
-191,768
-8% -$3.18M 0.01% 717
2025
Q4 		$47.2M Buy
2,486,792
+1,047,933
+73% +$15.1M 0.02% 650
2025
Q3 		$13.3M Buy
1,438,859
+1,069,981
+290% +$11.1M ﹤0.01% 969
2025
Q2 		$4.2M Sell
368,878
-11,270
-3% -$122K ﹤0.01% 1318
2025
Q1 		$4.52M Sell
380,148
-151,049
-28% -$2.53M ﹤0.01% 1291
2024
Q4 		$10M Sell
531,197
-323,485
-38% -$7.41M ﹤0.01% 1025
2024
Q3 		$19.2M Sell
854,682
-193,712
-18% -$4.39M 0.01% 843
2024
Q2 		$21.9M Sell
1,048,394
-450,974
-30% -$7.02M 0.01% 793
2024
Q1 		$22M Buy
1,499,368
+995,163
+197% +$10.7M 0.01% 785
2023
Q4 		$5.2M Buy
504,205
+484,610
+2,473% +$3.32M ﹤0.01% 1239
2023
Q3 		$154K Buy
19,595
+3,841
+24% +$35.1K ﹤0.01% 2938
2023
Q2 		$157K Sell
15,754
-12,659
-45% -$129K ﹤0.01% 3027
2023
Q1 		$252K Buy
28,413
+8,667
+44% +$90.3K ﹤0.01% 2896
2022
Q4 		$217K Buy
19,746
+310
+2% +$3.74K ﹤0.01% 2940
2022
Q3 		$253K Sell
19,436
-1,527
-7% -$24.2K ﹤0.01% 2804
2022
Q2 		$266K Buy
20,963
+3,011
+17% +$34.1K ﹤0.01% 2999
2022
Q1 		$252K Sell
17,952
-2,018
-10% -$35.8K ﹤0.01% 3128
2021
Q4 		$578K Buy
19,970
+677
+4% +$20.5K ﹤0.01% 2743
2021
Q3 		$578K Sell
19,293
-582
-3% -$18K ﹤0.01% 2929
2021
Q2 		$527K Buy
19,875
+4,130
+26% +$121K ﹤0.01% 3188
2021
Q1 		$490K Buy
15,745
+2,709
+21% +$102K ﹤0.01% 3115
2020
Q4 		$429K Buy
13,036
+7,105
+120% +$235K ﹤0.01% 3009
2020
Q3 		$207K Buy
+5,931
New +$149K ﹤0.01% 3193

Other funds holding NRIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return

Deutsche Bank's NRIX Position: Q3 2026 in Review

Deutsche Bank increased its Nurix Therapeutics (NRIX) stake by 143% in Q3 2026, buying an estimated $5.41M and bringing the position to 368,447 shares worth $8.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Deutsche Bank first reported a position in NRIX in Q3 2020 and has held it in 25 quarters since. The position peaked at $47.2M in Q4 2025. 68 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Deutsche Bank held 368,447 shares of Nurix Therapeutics worth $8.74M as of Q3 2026.
  • Deutsche Bank bought 216,994 Nurix Therapeutics shares in Q3 2026, an estimated $5.41M.
  • Nurix Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1029 holding.
  • Deutsche Bank first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 25 quarters since.
  • Deutsche Bank's Nurix Therapeutics position peaked at $47.2M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.